BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Asia's first therapeutic app gets approval in Japan

August 28, 2020 | News

The world's first app-based nicotine addiction treatment



Headquartered in Japan, CureApp, Inc. received regulatory authorization for the manufacturing and sale of Asia's first therapeutics app, the CureApp SC Nicotine Addiction Treatment App and CO Checker (hereafter, CureApp SC), from the Ministry of Health, Labour and Welfare (MHLW) on August 21st, 2020. The Company is currently proceeding with plans to receive insurance reimbursement and release CureApp SC in FY2020.

CureApp SC is a prescription medical device designed to aid patients who are receiving outpatient smoking cessation treatment. The device supports patients in their attempt to quit smoking in a home setting. The product consists of three components - a patient app, a doctor app, and a portable CO Checker.

The patient app is used in tandem with the portable CO Checker, allowing patients to accurately measure the concentration of carbon monoxide in their breath at home. Details on the patient's condition obtained from the patient app and the CO Checker will be shared with doctors via the doctor's app. The doctor app provides doctors with greater insight into the patient's response to treatments between check-ups.

Therapeutics apps, prescribed by doctors for medical conditions represent a new form of treatment that is attracting keen interest both in Japan and abroad. The safety and efficacy of CureApp SC has been demonstrated through clinical trials and, following preliminary approval from the Medical Devices and In-Vitro Diagnostics Working Group, Pharmaceutical Affairs and Food Sanitation Council of MHLW on June 19, CureApp SC received official regulatory approval by MHLW on August 21st.